甲状腺乳头状癌残灶消融前诊断性¹²³I全身扫描对临床管理的影响
回顾性分析152例甲状腺全切后拟行¹³¹I消融的甲状腺乳头状癌患者,比较内分泌科医生在不了解¹²³I全身扫描结果时推荐剂量与实际基于扫描结果所给剂量。49%病例两者不一致,作者认为消融前¹²³I全身扫描有重要作用。
要点
- 49%病例中,基于¹²³I全身扫描实际给予的¹³¹I剂量与不知扫描结果时推荐的剂量不同。
- 30%病例内分泌科医生推荐剂量低于实际给予剂量,12%推荐剂量高于实际给予剂量。
- 7%病例(11例)本可避免治疗,其中5例无¹³¹I摄取、6例为乳房¹³¹I摄取。
核心结论
- 作者认为消融前¹²³I全身扫描在甲状腺全切后拟行¹³¹I消融的甲状腺乳头状癌患者中可能有重要作用。
- 基于¹²³I全身扫描实际给予的¹³¹I剂量与不知扫描结果时推荐的剂量在49%的病例中不同。
研究设计与样本
- 回顾性分析2007年8月至2009年在本机构连续纳入的152例甲状腺全切后拟行¹³¹I消融的甲状腺乳头状癌患者,其中女性107例、男性45例,年龄13–82岁(均值±标准差:45.5±18.3岁)。
- 3名内分泌科医生在不知晓¹²³I全身扫描结果的情况下审阅患者资料(性别、年龄、病理、甲状腺球蛋白水平、抗甲状腺球蛋白抗体、促甲状腺激素水平及超声结果),并按规则推荐¹³¹I剂量:50–75 mCi用于残灶消融、75–125 mCi用于淋巴结转移、150 mCi用于肺转移、200 mCi用于骨转移。
- 将3名内分泌科医生推荐的剂量与治疗前¹²³I全身扫描后实际处方的¹³¹I剂量进行比较。
主要发现
- 3名内分泌科医生在98.7%的病例中推荐了相同剂量。
- 内分泌科医生推荐的剂量与基于¹²³I全身扫描结果实际给予的剂量在77例(51%)中一致。
- 46例(30%)中内分泌科医生本会给予较低剂量,18例(12%)中本会给予较高剂量,11例(7%)本会被不必要地治疗。
- 11例被不必要治疗的病例中,5例无¹³¹I摄取,6例有乳房¹³¹I摄取。
关键数值与推荐
- 美国甲状腺协会指南指出¹³¹I消融前全身扫描可能有用(评级C-专家意见)。
- 部分机构在常规临床方案中不在¹³¹I消融前进行¹²³I全身扫描。
- 剂量推荐规则:残灶消融50–75 mCi、淋巴结转移75–125 mCi、肺转移150 mCi、骨转移200 mCi。
临床怎么用
- 原文引用美国甲状腺协会指南:¹³¹I消融前全身扫描可能有用(评级C-专家意见)。
- 原文指出部分机构在常规临床方案中不在¹³¹I消融前进行¹²³I全身扫描。
- 作者认为消融前¹²³I全身扫描在拟行¹³¹I消融的甲状腺乳头状癌患者中可能有重要作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The use of I whole body scintigraphy (WBS) before I radioiodine ablation (RIA) of the post-surgical thyroid remnant in patients with papillary thyroid cancer (PTC) remains debated. The American Thyroid Association's guidelines state that WBS may be useful before RIA (rating C-expert opinion). Some institutions do not use I WBS before RIA in their routine clinical protocol. We were therefore prompted to evaluate the impact of I WBS prior to ablation of thyroid remnant in patients with PTC. METHODS: We reviewed data from 152 consecutive patients with PTC who had total thyroidectomy and were referred for RIA between August 2007 and February 2009 at our institution. The group included 107 women and 45 men, 13-82 years old (mean ± SD: 45.5 ± 18.3). Three endocrinologists blinded to the results of the I WBS reviewed patients' data including sex, age, pathology, thyroglobulin (Tg) level, anti-Tg antibodies, thyroid stimulating hormone (TSH) level and ultrasound results. Each endocrinologist then returned a form with the recommended I dose for each participant, according to the following rules: 50-75 mCi (remnant ablation), 75-125 mCi (lymph nodes metastases), 150 mCi (lung metastases), and 200 mCi (bone metastases). We compared their recommended doses with the actual I doses prescribed after the pre-therapy I WBS. RESULTS: All three endocrinologists recommended the same dose in 98.7% of the cases. The dose prescribed by the endocrinologists matched the dose administered after analyzing the I WBS in 77 patients (51%). However, for 46 patients (30%) the endocrinologists would have given a lower dose, for 18 patients (12%) a higher dose than that administered based on the results of the I WBS, while 11 patients (7%) would have been treated unnecessarily (5/11 had no I uptake and 6/11 had I uptake in the breasts). CONCLUSIONS: Our study suggests a significant role of the pre-therapy I WBS in PTC patients referred for I ablation post-thyroidectomy. The actual I dose that was administered based on the I WBS differed from the dose recommended in the absence of the I WBS in 49% of the cases.
引用
- Song H, Mosci C, Akatsu H, et al. Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management. Clin Nucl Med. 2018. PMID: 30153149. doi:10.1097/RLU.0000000000002246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。